Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biodegradable Stent Relieves Esophageal Constriction

By HospiMedica International staff writers
Posted on 23 Aug 2011
A new biodegradable (BD) esophageal stent provides a comfortable and patient-friendly option to repeated balloon dilation procedures in patients with achalasia and peptic, anastomotic, and caustic strictures.

The BD Stent is made of polydioxanone (PDS), and is intended for the treatment of narrowing and tightening of the esophagus, which is traditionally treated by balloon dilatation, a treatment option that often has to be repeated whenever the esophagus contracts, causing discomfort for the patient and also necessitating repeat admission to a hospital. More...
Among the features of BD Stent are sustained integrity and radial force, maintained for 6-8 weeks (pH dependent); a modified dual “flared-end” design reduces the risk of stent migration; and radiopaque markers at each end and midpoint assist precise positioning.

The BD Stent dissolves in a period of 11-12 weeks, similar to that of dissolvable sutures. The stent offers a reduced need for repeated balloon dilatation, improved patient comfort and satisfaction, fewer hospital admissions, and reduced costs. The BD Stent is a product of UK Medical (Sheffield, United Kingdom). It is available in a standard diameter of 25 mm, and lengths of 60 mm, 80 mm, 115 mm, and 135 mm; 18 mm, 20 mm, and 23 mm diameters are available upon request.

“It’s a very impressive piece of technology that provides real benefit to the patient, as well as providing long term cost savings to the NHS,” said Ian Aaron, Managing Director of UK Medical. “The BD Stent fits UK Medical’s product range perfectly, we never lose sight of the human story at the heart of every request for medical products and we put customers and patients first.”

Achalasia is an esophageal motility disorder involving the smooth muscle layer of the esophagus and the lower esophageal sphincter (LES); its causes are unknown. It is characterized by incomplete LES relaxation, increased LES tone, and inability of smooth muscle to move food down the esophagus in the absence of other explanations like cancer or fibrosis. Various treatments are available, although none cures the condition. Certain medications or Botox may be used in some cases, but more permanent relief is brought by esophageal dilatation and surgical cleaving of the muscle.

Related Links:

UK Medical




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.